Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
about
Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerAccurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersHormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Fulvestrant in advanced breast cancer: evidence to date and place in therapy.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016.Defining the optimal sequence for the systemic treatment of metastatic breast cancer.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.Current challenges of metastatic breast cancer.Prospects and progress of antibody-drug conjugates in solid tumor therapies.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).Metastatic breast cancer: The Odyssey of personalization.Bilateral Salpingo-Oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word settingCyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research.Metastatic breast cancer: Endocrine therapy landscape reshaped.Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.New agents for the management of resistant metastatic breast cancer.Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.Parallel factor ChIP provides essential internal control for quantitative differential ChIP-seq.Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.A Review of Fulvestrant in Breast Cancer.Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer.
P2860
Q26770482-DAB31EF8-F97D-42B4-B6E0-F83AAD2AE2A1Q28069856-09E0BC99-11DE-405F-AB10-5A6E8BA392E2Q33656801-9C2B7B2D-89A5-4D09-AFC1-E4EA399754E4Q33887675-F1047483-B7E6-4838-B076-310808AE3D09Q34534031-C41CCB04-74AB-4ABB-8CB2-8B8BD9DF49E6Q36924682-1CF93B2F-A6C6-4937-A415-67BD4374B2CAQ37045421-3FF2D4B6-B454-4468-A9C2-561936D2F75EQ37573430-C65F2D7D-CA7B-488D-B143-EF3F3191FDF4Q37588645-449EEDC4-C20D-45D0-B81C-9AFC6A5EB355Q38573858-4B0DF730-39B1-466A-A18A-E3B6091DF360Q38658647-3A5EA7D7-87D0-4390-ABDE-1F311883731CQ38719706-152057DB-2468-49BC-A6E2-F08A1FA4D387Q38765017-40D02FEC-9FCE-4E36-987C-2F5B09DD026AQ38784116-682500BE-9F5A-41C8-B642-3BE19F472460Q38785362-D819F126-88FF-48B2-8673-3D5075DEEE73Q38798525-0F44830B-CEA4-462D-AE97-FBCE71BEB622Q38861026-3807CEDE-B36F-4DF1-8778-03FB49D4D7F8Q38880515-32D6DB9C-BDB5-49CA-BB84-3D357C47E0ECQ38901163-B61BEABE-AAC3-4A48-BCA0-92FE6B442963Q38933076-84224B0C-75FF-4E7F-A3D6-A347FE3D2385Q38933237-77ECC549-ABD0-4702-9389-B4EDCFF78E1EQ39703687-F0DBAACD-814F-4F67-B250-E46396055626Q39767266-59C88D6F-DCD9-4BA8-A422-BA43B0154D4DQ41551635-F12DC12E-21AF-4AAD-B457-DF4AD1DCA400Q41969578-2D334D62-DFAA-4E46-B069-23D1FDF5E9B3Q42345385-05198761-3792-4F71-9C2F-BDCA3BD96264Q42357121-40527729-9F77-4BBE-9316-2F0B2ABAC47FQ45072397-D42B7A1F-B3C5-4B41-AE12-E96C2D384308Q47409996-D2B50DDC-85EC-4B38-9193-4D7972F56C31Q47561979-810B0CF0-1381-4CE5-A7F8-5B8B21BFDF0DQ47592237-972FE747-1F2F-4BC3-80B5-1B8B5F4F05B1Q48180960-7CC386A0-E4F1-4A4A-AAFB-9C3307D426DEQ48240854-B2E34A6B-536C-42FB-ABCA-ABA74FE82E77Q49632496-429FD310-52E9-430C-A95A-6D9082076E03Q52577825-31556067-BE28-4529-8055-CC1EBE9B4396Q52739363-F241F701-9945-4B60-B2D4-901F935EF7DDQ53183982-0710D36A-6256-46B9-9CF7-E803E5546F83Q53733893-E3BDAFE4-750D-4074-AE89-230B54323EC5Q54957190-03316531-8CD0-4693-A79C-F8707DD76B84Q55275883-D3D8C414-F430-46C2-B732-5E8E49A4FBD8
P2860
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Fulvestrant 500 mg Versus Anas ...... From the Phase II FIRST Study.
@ast
Fulvestrant 500 mg Versus Anas ...... From the Phase II FIRST Study.
@en
type
label
Fulvestrant 500 mg Versus Anas ...... From the Phase II FIRST Study.
@ast
Fulvestrant 500 mg Versus Anas ...... From the Phase II FIRST Study.
@en
prefLabel
Fulvestrant 500 mg Versus Anas ...... From the Phase II FIRST Study.
@ast
Fulvestrant 500 mg Versus Anas ...... From the Phase II FIRST Study.
@en
P2093
P2860
P356
P1476
Fulvestrant 500 mg Versus Anas ...... From the Phase II FIRST Study.
@en
P2093
Antonio Llombart-Cussac
David Feltl
John A Dewar
John F R Robertson
Marek Jasiówka
Matthew J Ellis
Nicola Hewson
Yuri Rukazenkov
P2860
P304
P356
10.1200/JCO.2015.61.5831
P407
P577
2015-09-14T00:00:00Z